CA-FORESCOUT
Forescout, a global cybersecurity leader and a key provider of cybersecurity solutions to the U.S. Department of Defense (DoD), announced today that it secured a new contract with the DoD as it enters year four of the highly successful Comply-to-Connect (C2C) program. The program’s next stage will be to configure delivered capabilities to enforce zero trust access principles across the DoD Information Network (DoDIN) enterprise and bring the DoD closer to the goals set forth in the Department’s Zero Trust Strategy.
As advocated by the Defense Information System Agency (DISA) C2C Program Management Office (PMO), the new contract also delivers additional capabilities to the C2C platform that revolutionize security of Operational Technology networks and integrates risk management and decision making into the existing C2C platform. This addition further positions the DoD to apply NIST zero trust principles to millions of devices across the enterprise. Implementation of zero trust principles using Forescout’s C2C capabilities is already being accomplished in some areas of the Army, via an initiative being taught at Fort Gordon school houses and referenced in Defense Acquisition University.
With the first three steps of the program – visibility, compliance assessment, and automated remediation – well underway, administrators can now use Forescout’s orchestration capabilities to manage policy enforcement points to create the desired effects on an individual user/device/access request basis. Additionally, Forescout’s continuous monitoring capabilities are at work to ensure connected devices don’t fall out of compliance due to files getting corrupted, simple administrative mistakes, or malicious adversarial actions, all of which occur daily on the DoDIN.
C2C is one of the largest government cybersecurity initiatives in the world delivering enterprise scale capabilities for managing cyber operational risk. With the program now in its fourth year, automated control of access to and within the DoDIN will ensure that each network user has the access necessary to achieve their mission without exposing other users to threats that could impact their ability to complete their mission.
“We are proud to once again be trusted by so many organizations to secure the backbone of their operations: the networks that connect everything,” said Barry Mainz, CEO, Forescout. “Each DoDIN user should have confidence that their slice of the network is secure and ready for them to accomplish their mission. That’s what we are delivering through C2C.”
Today, the Forescout platform provides comprehensive capabilities for the DoD’s C2C security framework that enables the critical first pillar of DISA’s zero trust program called Thunderdome. This includes:
- Network-based discovery and classification of assets, including an expanding set of “unmanaged” assets that are unable to operate agents (C2C Steps 1 and 2)
- Integration with other enterprise solutions such as Identity, Credential, and Access Management (ICAM); Security Information Event Management (SIEM); and Vulnerability Assessment products to automate compliance of the cybersecurity posture and establish trust for every connecting asset (C2C Step 3)
- Orchestration of policy enforcement points across the infrastructure to enforce network access control and segmentation of assets as well as complete situational awareness of the network posture (C2C Steps 4 and 5)
“We look forward to introducing cloud-based advanced threat analysis tools into the C2C program’s portfolio of capabilities and adding further value on DoD’s zero trust journey,” added Mainz. “We’ve really just begun to unleash the power of our platform within the DoD. The best is still ahead.”
Additional Resources
- Forescout C2C Overview
- Achieving Comply-to-Connect requirements with the Forescout platform
- DoD Zero Trust Strategy
- DISA Thunderdome Presentation at AFCEA TechNet-Cyber
About Forescout
Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats. www.forescout.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914036853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
